Oxidative Stress as a Therapeutic Target of Alzheimer’s Disease—2nd Edition

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 713

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, Bari, Italy
Interests: cell culture; transfection; cancer biology; pharmaceutical biotechnology; medicinal chemistry

E-Mail Website
Guest Editor
Dipartimento di Farmacia—Scienze del Farmaco, Università degli Studi di Bari, Bari, Italy
Interests: medicinal chemistry; serotonin receptors; dopamine receptors; formyl peptide receptors; positron emission tomography; fluorescent ligands
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following the success of the first edition of our Special Issue, which resulted in the compilation of interesting and inspiring research and review papers, we are happy to announce its second edition, entitled “Oxidative Stress as a Therapeutic Target of Alzheimer’s Disease—2nd Edition”.

Once again, we will focus on the current advances regarding antioxidant research for the development of new drugs targeting the onset and progression of Alzheimer's Disease (AD). While the oxidative stress phenomena that accompany neuroinflammation are strongly linked to the neurodegeneration that leads to cognitive symptoms, antioxidant therapy is still controversial and lacks any clinical substantiation.

This field of research is, however, still highly dynamic and diverse, comprising different strategies such as the employment of scavenger compounds and enzyme inhibition. The goal of this Special Issue is to gather the latest research regarding the physiopathology of oxidative stress in AD and the development of new therapeutic agents targeting this phenomenon. All approaches to this are welcome.

We eagerly look forward to your contributions.

Dr. Leonardo Brunetti
Prof. Marcello Leopoldo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer's disease
  • oxidative stress
  • therapeutic target
  • antioxidant
  • neurodegeneration

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

32 pages, 1384 KB  
Review
Beyond Radical Scavengers: Focus on NADPH Oxidases (NOX) Inhibitors as New Agents for Antioxidant Therapy in Alzheimer’s Disease
by Leonardo Brunetti, Fabio Francavilla, Angela Santo, Daniele Vitone, Marcello Leopoldo and Enza Lacivita
Antioxidants 2026, 15(1), 17; https://doi.org/10.3390/antiox15010017 - 22 Dec 2025
Viewed by 577
Abstract
Over the past decade, oxidative stress and neuroinflammation have been increasingly recognized as part of the pathology of Alzheimer’s disease (AD). This observation has led to extensive efforts and attempts to apply antioxidant compounds as therapeutic agents for AD and other pathologies. However, [...] Read more.
Over the past decade, oxidative stress and neuroinflammation have been increasingly recognized as part of the pathology of Alzheimer’s disease (AD). This observation has led to extensive efforts and attempts to apply antioxidant compounds as therapeutic agents for AD and other pathologies. However, most, if not all, of these attempts have failed in preclinical or clinical trials. A tentative explanation for this failure is radical scavengers’ intrinsic lack of specificity in either their mode or district of action. The lack of specificity has been thought by some to be a source of so-called “reductive stress”, another form of redox imbalance that might be just as toxic as oxidative stress. Thus, research interest is shifting from developing simple radical scavengers to designing and refining compounds targeting the overproduction of Reactive Oxygen Species (ROS) in specific pathological conditions. This can be achieved, for instance, by targeting the enzymes that are mainly responsible for their production, namely NADPH oxidases (NOX). In this review, we will discuss, from the point of view of medicinal chemistry, the main innovations in the development of NOX inhibitors and their potential employment for AD therapy. We will also discuss the experimental hurdles that slow down research in this field and possible solutions. Full article
Show Figures

Graphical abstract

Back to TopTop